We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
ANRO is advancing ALTO-207 through three clinical studies targeting treatment-resistant depression.
ALTO-207's phase IIb results are expected in the second half of 2027, with phase III studies planned.
ALTO-300 and ALTO-100 phase IIb top-line results are expected in the first half and mid-2027, respectively.
Alto Neuroscience (ANRO - Free Report) is a clinical-stage biopharmaceutical company focused on developing medicines for mental health disorders, including depression, bipolar depression and schizophrenia-related cognitive impairment. The company uses a precision psychiatry approach, which involves studying brain-based biomarkers to identify patients who may respond better to specific treatments. This strategy could help address a key limitation of conventional psychiatric medicines. However, the company has no approved commercial products, and its future success depends on clinical study results and regulatory progress.
The company’s pipeline comprises several assets, notably ALTO-207, ALTO-300, ALTO-100 and ALTO-101.
Year to date, shares of Alto have risen 24.1% compared with the industry’s 2.9% growth.
Image Source: Zacks Investment Research
Progress Across ANRO’s Pipeline Programs
ALTO-207 is one of Alto’s key pipeline candidates being developed to treat treatment-resistant depression (TRD), a condition in which patients do not respond adequately to existing therapies. The candidate combines pramipexole, a dopamine agonist approved for Parkinson’s disease that has demonstrated antidepressant effects and ondansetron, a 5-HT3 receptor antagonist used to prevent nausea. The combination is designed to improve tolerability and allow faster dose increases and higher pramipexole dosing.
In mid-2026, the company reported encouraging phase IIa results in major depressive disorder, supporting further development of this treatment approach. The study demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability. Alto is advancing ALTO-207 through its PACE program, which includes three clinical studies for TRD. The ongoing phase IIb PACE-1 study is evaluating ALTO-207 as an add-on, with topline results expected in the second half of 2027. The company plans to start the phase III PACE-2 study of ALTO-207 as an add-on treatment by early 2027. The additional phase III PACE-3 study will evaluate it as a standalone treatment, with initiation expected in the second half of 2027, subject to FDA alignment. Running these studies in parallel could accelerate development and potentially support a broader product label. Alto also expects its patents to protect ALTO-207 through at least the mid-2040s, supporting its long-term commercial potential.
Alto’s other key pipeline candidates, ALTO-300 and ALTO-100, offer additional growth opportunities. ALTO-300 is being developed as an add-on treatment for major depressive disorder, with an electroencephalogram biomarker used to identify patients who may benefit from the therapy. ALTO-100 is being evaluated for bipolar depression in patients selected using a cognitive biomarker. Both candidates are currently in phase IIb studies.
Alto expects to report top-line results for ALTO-300 in the first half of 2027 and for ALTO-100 around mid-2027. Positive clinical data from either program could support further development and expand Alto’s growth prospects in mental health.
Alto is also developing ALTO-101 to address cognitive impairment associated with schizophrenia, which can affect memory, attention and daily functioning. The candidate’s phase II proof-of-concept study failed to meet statistical significance on the primary endpoint in April 2026. However, some secondary and exploratory analyses showed encouraging signals. These findings are not sufficient to establish the treatment’s efficacy. Alto has since developed a modified-release oral formulation and plans to explore potential partnering opportunities for the candidate.
Over the past 60 days, estimates for ANRO’s 2026 loss per share have narrowed from $3.00 to $2.68, while 2027 loss per share estimates have improved from $3.46 to $3.04.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.6% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Key Takeaways
Alto Neuroscience (ANRO - Free Report) is a clinical-stage biopharmaceutical company focused on developing medicines for mental health disorders, including depression, bipolar depression and schizophrenia-related cognitive impairment. The company uses a precision psychiatry approach, which involves studying brain-based biomarkers to identify patients who may respond better to specific treatments. This strategy could help address a key limitation of conventional psychiatric medicines. However, the company has no approved commercial products, and its future success depends on clinical study results and regulatory progress.
The company’s pipeline comprises several assets, notably ALTO-207, ALTO-300, ALTO-100 and ALTO-101.
Year to date, shares of Alto have risen 24.1% compared with the industry’s 2.9% growth.
Image Source: Zacks Investment Research
Progress Across ANRO’s Pipeline Programs
ALTO-207 is one of Alto’s key pipeline candidates being developed to treat treatment-resistant depression (TRD), a condition in which patients do not respond adequately to existing therapies. The candidate combines pramipexole, a dopamine agonist approved for Parkinson’s disease that has demonstrated antidepressant effects and ondansetron, a 5-HT3 receptor antagonist used to prevent nausea. The combination is designed to improve tolerability and allow faster dose increases and higher pramipexole dosing.
In mid-2026, the company reported encouraging phase IIa results in major depressive disorder, supporting further development of this treatment approach. The study demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability. Alto is advancing ALTO-207 through its PACE program, which includes three clinical studies for TRD. The ongoing phase IIb PACE-1 study is evaluating ALTO-207 as an add-on, with topline results expected in the second half of 2027. The company plans to start the phase III PACE-2 study of ALTO-207 as an add-on treatment by early 2027. The additional phase III PACE-3 study will evaluate it as a standalone treatment, with initiation expected in the second half of 2027, subject to FDA alignment. Running these studies in parallel could accelerate development and potentially support a broader product label. Alto also expects its patents to protect ALTO-207 through at least the mid-2040s, supporting its long-term commercial potential.
Alto’s other key pipeline candidates, ALTO-300 and ALTO-100, offer additional growth opportunities. ALTO-300 is being developed as an add-on treatment for major depressive disorder, with an electroencephalogram biomarker used to identify patients who may benefit from the therapy. ALTO-100 is being evaluated for bipolar depression in patients selected using a cognitive biomarker. Both candidates are currently in phase IIb studies.
Alto expects to report top-line results for ALTO-300 in the first half of 2027 and for ALTO-100 around mid-2027. Positive clinical data from either program could support further development and expand Alto’s growth prospects in mental health.
Alto is also developing ALTO-101 to address cognitive impairment associated with schizophrenia, which can affect memory, attention and daily functioning. The candidate’s phase II proof-of-concept study failed to meet statistical significance on the primary endpoint in April 2026. However, some secondary and exploratory analyses showed encouraging signals. These findings are not sufficient to establish the treatment’s efficacy. Alto has since developed a modified-release oral formulation and plans to explore potential partnering opportunities for the candidate.
Alto Neuroscience, Inc. Price and Consensus
Alto Neuroscience, Inc. price-consensus-chart | Alto Neuroscience, Inc. Quote
ANRO's Zacks Rank & Estimates
Alto currently carries a Zacks Rank #2 (Buy).
Over the past 60 days, estimates for ANRO’s 2026 loss per share have narrowed from $3.00 to $2.68, while 2027 loss per share estimates have improved from $3.46 to $3.04.
Other Stocks to Consider
Some other better-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.6% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.